ARS Pharmaceuticals (SPRY) EPS (Weighted Average and Diluted) (2021 - 2025)
ARS Pharmaceuticals (SPRY) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.42 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) fell 182.35% to -$0.42 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.75 through Dec 2025, down 2600.0% year-over-year, with the annual reading at -$1.74 for FY2025, 2275.0% down from the prior year.
- EPS (Weighted Average and Diluted) hit -$0.42 in Q4 2025 for ARS Pharmaceuticals, up from -$0.52 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.19 in Q4 2021 to a low of -$0.65 in Q3 2021.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.1 across 5 years, with a median of -$0.2 in 2023.
- Biggest five-year swings in EPS (Weighted Average and Diluted): surged 828.57% in 2024 and later tumbled 253.85% in 2025.
- Year by year, EPS (Weighted Average and Diluted) stood at $1.19 in 2021, then decreased by 25.21% to $0.89 in 2022, then tumbled by 107.87% to -$0.07 in 2023, then soared by 828.57% to $0.51 in 2024, then tumbled by 182.35% to -$0.42 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for SPRY at -$0.42 in Q4 2025, -$0.52 in Q3 2025, and -$0.46 in Q2 2025.